| Literature DB >> 30626759 |
Shigeyuki Shichino1,2, Satoshi Ueha1,2, Shinichi Hashimoto1,2,3, Mikiya Otsuji1,2, Jun Abe1,4, Tatsuya Tsukui1, Shungo Deshimaru1,2, Takuya Nakajima1,2, Mizuha Kosugi-Kanaya1, Francis Hw Shand1, Yutaka Inagaki5, Hitoshi Shimano6, Kouji Matsushima1,2.
Abstract
Pulmonary fibrosis (PF) is an intractable disorder with a poor prognosis. Although lung fibroblasts play a central role in PF, the key regulatory molecules involved in this process remain unknown. To address this issue, we performed a time-course transcriptome analysis on lung fibroblasts of bleomycin- and silica-treated murine lungs. We found gene modules whose expression kinetics were associated with the progression of PF and human idiopathic PF (IPF). Upstream analysis of a transcriptome network helped in identifying 55 hub transcription factors that were highly connected with PF-associated gene modules. Of these hubs, the expression of Srebf1 decreased in line with progression of PF and human IPF, suggesting its suppressive role in fibroblast activation. Consistently, adoptive transfer and genetic modification studies revealed that the hub transcription factor SREBP-1c suppressed PF-associated gene expression changes in lung fibroblasts and PF pathology in vivo. Moreover, therapeutic pharmacological activation of LXR, an SREBP-1c activator, suppressed the Srebf1-dependent activation of fibroblasts and progression of PF. Thus, SREBP-1c acts as a protective hub of lung fibroblast activation in PF. Collectively, the findings of the current study may prove to be valuable in the development of effective therapeutic strategies for PF.Entities:
Keywords: Bioinformatics; Fibrosis; Inflammation; Mouse models; Pulmonology
Year: 2019 PMID: 30626759 PMCID: PMC6485671 DOI: 10.1172/jci.insight.122163
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708